PI3K/Akt/CREB activator 1|cas:2708177-73-3|西域试剂

PI3K/Akt/CREB activator 1,99.10%

产品编号：Bellancom-151527| CAS NO：2708177-73-3| 分子式：C₁₉H₁₅F₄NO₃| 分子量：381.32

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-151527	￥1200.00	杭州北京（现货）
Bellancom-151527	￥2000.00	杭州北京（现货）
Bellancom-151527	￥3900.00	杭州北京（现货）
Bellancom-151527	￥6000.00	杭州北京（现货）
Bellancom-151527	￥9000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

PI3K/Akt/CREB activator 1

产品介绍

PI3K/Akt/CREB activator 1 (compound AE-18) 是一种口服有效的 PI3K/Akt/CREB 的激活剂。PI3K/Akt/CREB activator 1 通过 PI3K/Akt/CREB 通路上调脑源性神经营养因子，促进神经元增殖，诱导 Neuro-2a 细胞分化成神经元样形态，加速海马原代神经元轴突-树突极化的建立。PI3K/Akt/CREB activator 1 可用于血管性痴呆 (VaD) 的研究。

生物活性

PI3K/Akt/CREB activator 1 (compound AE-18) is a potent, orally active PI3K/Akt/CREB activator. PI3K/Akt/CREB activator 1 promotes neuronal proliferation, induced differentiation of Neuro-2a cells into a neuron-like morphology, and accelerated the establishment of axon-dendrite polarization of primary hippocampal neurons through upregulating brain-derived neurotrophic factor via the PI3K/Akt/CREB pathway. PI3K/Akt/CREB activator 1 can be used in research of vascular dementia (VaD).

体外研究

PI3K/Akt/CREB activator 1 (compound AE-18; 10 and 20 μM; 48 h) induces neurite outgrowth and proliferation through upregulating BDNF via the PI3K/Akt/CREB pathway Neuro-2a cells.
PI3K/Akt/CREB activator 1 (10 and 20 μM; neurons) enhances neuronal differentiation and axon-dendrite polarization in cultured hippocampal neurons through the PI3K/AKT signal pathway.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	Neuro-2a cells
Concentration:	10 and 20 μM
Incubation Time:	48 hours
Result:	Increased the expressions of BDNF and the phosphorylated form of AKT (pAKT) and CREB (pCREB).

体内研究
(In Vivo)

PI3K/Akt/CREB activator 1 (compound AE-18; 5 and 10 mg/kg; i.g.; male Sprague-Dawley rats with chronic cerebral hypoperfusion (CCH) model) improves cerebral blood flow (CBF) recovery after bilateral common carotid artery occlusion (BCCAO).
PI3K/Akt/CREB activator 1 (5 and 10 mg/kg; i.g.; for 5 d) mitigates impairment of learning and memory in chronic cerebral hypoperfusion (CCH) rat model and alleviates CCH-induced pathological injury in the hippocampus after BCCAO.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats (200-220 g) with chronic cerebral hypoperfusion (CCH) model
Dosage:	5 and 10 mg/kg
Administration:	Oral gavage; daily, for 6 weeks
Result:	Promoted the recovery of CBF after BCCAO.

Animal Model:	Male Sprague-Dawley rats (200-220 g) with chronic cerebral hypoperfusion (CCH) model
Dosage:	5 and 10 mg/kg
Administration:	Oral gavage; daily, for 5 days
Result:	Reduced escape latency from day 1 to day 5 of the morris water maze (MWM) test compared with the CCH group. Improved cognitive deficits in CCH rat model.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats (200-220 g) with chronic cerebral hypoperfusion (CCH) model
Dosage:	5 and 10 mg/kg
Administration:	Oral gavage; daily, for 6 weeks
Result:	Promoted the recovery of CBF after BCCAO.

Animal Model:	Male Sprague-Dawley rats (200-220 g) with chronic cerebral hypoperfusion (CCH) model
Dosage:	5 and 10 mg/kg
Administration:	Oral gavage; daily, for 5 days
Result:	Reduced escape latency from day 1 to day 5 of the morris water maze (MWM) test compared with the CCH group. Improved cognitive deficits in CCH rat model.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats (200-220 g) with chronic cerebral hypoperfusion (CCH) model
Dosage:	5 and 10 mg/kg
Administration:	Oral gavage; daily, for 6 weeks
Result:	Promoted the recovery of CBF after BCCAO.

Animal Model:	Male Sprague-Dawley rats (200-220 g) with chronic cerebral hypoperfusion (CCH) model
Dosage:	5 and 10 mg/kg
Administration:	Oral gavage; daily, for 5 days
Result:	Reduced escape latency from day 1 to day 5 of the morris water maze (MWM) test compared with the CCH group. Improved cognitive deficits in CCH rat model.

性状

Solid

溶解性数据

In Vitro:

DMSO : 250 mg/mL (655.62 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.6225 mL	13.1123 mL	26.2247 mL
5 mM	0.5245 mL	2.6225 mL	5.2449 mL
10 mM	0.2622 mL	1.3112 mL	2.6225 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (5.45 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.45 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (5.45 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.45 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。